Our purpose is to make
a difference for patients
Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T cell redirecting immunotherapies for the treatment of cancer. Immatics is sponsoring several clinical trials to deliver the power of T cells to cancer patients. The purpose of these trials is to develop innovative immunotherapies aimed at targeting a patient’s tumor selectively and effectively.
We have a big goal: overcome the challenges of fighting cancer and bring new therapeutic products to cancer patients. We do this with a singular passion and relentless focus to achieve better outcomes for patients.
Clinical
Trials
The following three clinical trials are currently open and recruiting patients:
The IMA203-101 trial (NCT03686124) is evaluating the safety, tolerability, and initial signs of clinical efficacy of ’ACTengine® IMA203. IMA203 is a cell therapy approach and targets preferentially expressed antigen in melanoma (PRAME), in patients with recurrent and/or refractory solid tumors.
Among a broad range of solid cancer indications, uterine cancer (endometrial cancer and uterine carcinoma), ovarian cancer, melanoma, several subtypes of sarcoma and squamous NSCLC are of special interest because the PRAME peptide is expressed in these tumors with a very high frequency.
For more information on this clinical trial, click here
The IMA401-101 trial (NCT05359445) is evaluating safety, tolerability, and initial anti-tumor activity of TCER® IMA401 in patients with recurrent and/or refractory solid tumors. TCER® IMA401 is a TCR Bispecific molecule, which targets MAGEA4/8 and will be developed in collaboration with Bristol Myers Squibb.
The Phase 1 trial investigates IMA401 in patients with tumors of high MAGEA4/8 prevalence, such as squamous non-small cell lung carcinoma (sqNSCLC), small cell lung cancer (SCLC), head and neck squamous cell carcinoma (HNSCC), bladder, uterine, esophageal and ovarian carcinomas, as well as melanoma, sarcoma subtypes and other solid cancer types.
For more information on this clinical trial, click here
The IMA402-101 trial (NCT05958121) is evaluating safety, tolerability, and anti-tumor activity of TCER® IMA402 in patients with recurrent and/or refractory solid tumors. TCER® IMA402 is a TCR Bispecific molecule targeting PRAME.
The Phase 1/2 trial investigates IMA402 in patients with tumors of high PRAME prevalence, such as cutaneous and uveal melanoma, ovarian cancer, lung cancer, uterine cancer, synovial sarcoma and other solid cancer types.
For more information on this clinical trial, click here
Active Clinical
Trial Sites:
USA:
The University of Texas MD Anderson Cancer Center – Houston, Texas
Columbia University Irving Medical Center – New York, New York
University of Chicago Medicine – Chicago, Illinois
UPMC Hillman Cancer Center – Pittsburgh, Pennsylvania
Europe:
Universitätsklinikum Bonn – Bonn, Germany
Klinikum Chemnitz Klinik für Innere Medizin III – Chemnitz, Germany
Universitätsklinikum Carl Gustav Carus Dresden – Dresden, Germany
Marien Hospital Düsseldorf – Düsseldorf, Germany
Universitätsklinikum Erlangen Interdisciplinary Clinical Trial Unit with ECTU – Erlangen, Germany
Universitätsklinikum Hamburg-Eppendorf – Hamburg, Germany
Comprehensive Cancer Center Tübingen-Stuttgart – Tübingen, Germany
Universitätsklinikum Würzburg – Würzburg, Germany
Universitätsklinikum Freiburg – Freiburg, Germany
UKHD Nationales Zentrum für Tumorkrankheiten – Heidelberg, Germany
Universitätsklinikum Ulm Zentrum für Innere Medizin Klinik für Innere Medizin III – Ulm, Germany
Klinikum rechts der Isar der TU München – München, Germany
Klinikum Nürnberg – Nürnberg, Germany
Universitätsklinikum Regensburg – Regensburg, Germany
Universitätsklinikum Münster – Münster, Germany
Universitätsmedizin der Johannes Gutenberg – Universität Mainz – Mainz, Germany
Charité Benjamin Franklin – Berlin, Germany
Universitäres Krebszentrum Leipzig (UCCL) – Leipzig, Germany
If you are a patient and interested participating in one of Immatics’ clinical trials, please speak to your treating physician.